StemCells (STEM) Provided Data on Phase I/II Trial in Spinal Cord Injury
Tweet Send to a Friend
StemCells, Inc. (Nasdaq: STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
